Literature DB >> 11152654

Kinetics of the inhibition of proteinase 3 by elafin.

Q L Ying1, S R Simon.   

Abstract

Excessive proteolytic activity of proteinase 3 (Pr3) has been suggested to be a factor contributing to the pathogenesis of emphysema and other inflammatory disorders. We report here on the kinetics of inhibition of Pr3 by one of its major endogenous inhibitors, the 6-kD inhibitory domain of elafin. The results are consistent with a reaction mechanism in which a single elafin molecule binds a single Pr3 molecule to form a fully reversible complex. The association and dissociation rate constants, and the inhibition constant were measured to be 4.0 x 10(6) M(-1) s(-1), 1.7 x 10(-3) s(-1), and 4.2 x 10(-10) M, respectively. Triton X-100 and dimethyl sulfoxide, which are frequently added in assay mixtures for enzymatic analysis of Pr3 activity, significantly reduced the association rate. A fraction of the total neutrophil content of Pr3 has been reported to be bound to the surface of the plasma membrane of activated and nonactivated neutrophils. In this study, we also measured the reaction rate constants of elafin with Pr3 that had been previously allowed to associate with phospholipid bilayer vesicles. Binding to the model membranes slowed down the association rate to 3.3 x 10(5) M(-1) s(-1), but the membrane-bound Pr3 and elafin formed a more stable complex, with a dissociation rate constant of 9.1 x 10(-4) s(-1). Based on the kinetic parameters determined here and the estimated elafin concentrations in vivo, it may be concluded that elafin plays a limited role in the regulation of proteolytic activity of Pr3 in lung secretions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152654     DOI: 10.1165/ajrcmb.24.1.4300

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  6 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3.

Authors:  Sixin Tian; Joakim E Swedberg; Choi Yi Li; David J Craik; Simon J de Veer
Journal:  ACS Med Chem Lett       Date:  2019-07-19       Impact factor: 4.345

3.  Novel role of the serine protease inhibitor elafin in gluten-related disorders.

Authors:  Heather J Galipeau; Michelle Wiepjes; Jean-Paul Motta; Jessica D Schulz; Jennifer Jury; Jane M Natividad; Ines Pinto-Sanchez; Daniel Sinclair; Perrine Rousset; Rebeca Martin-Rosique; Luis Bermudez-Humaran; Jean Christophe Leroux; Joseph A Murray; Edgardo Smecuol; Julio C Bai; Nathalie Vergnolle; Philippe Langella; Elena F Verdu
Journal:  Am J Gastroenterol       Date:  2014-04-08       Impact factor: 10.864

4.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

5.  Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.

Authors:  Alain Doucet; Dominique Bouchard; Marie France Janelle; Audrey Bellemare; Stéphane Gagné; Guy M Tremblay; Yves Bourbonnais
Journal:  Biochem J       Date:  2007-08-01       Impact factor: 3.857

Review 6.  Alpha-1 Antitrypsin-A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis.

Authors:  Alison M D Hunt; Arlene M A Glasgow; Hilary Humphreys; Catherine M Greene
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.